Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript [Seeking Alpha]
Minerva Neurosciences, Inc (NERV)
Last minerva neurosciences, inc earnings: 3/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.minervaneurosciences.com/investor-relations
Company Research
Source: Seeking Alpha
Company Participants Rémy Luthringer - Executive Chairman & CEO Conference Call Participants Gregory Strauss Brian W. Kirkpatrick Corey Davis - Lifesci Advisors, LLC Lin Tsai - Jefferies LLC, Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, and welcome to the Minerva Neurosciences Virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Minerva website following the conclusion of the event. I'd now like to turn the call over to your host, Remy Luthringer, Executive Chairman and Chief Executive Officer at Minerva Neurosciences. Please go ahead, Remy. Rémy Luthringer Executive Chairman & CEO Thank you so much. Good morning, everybody. It's a real great pleasure to give you an update on Minerva progress in bringing roluperidone to patients afflicted by schizophrenia and suffering from negative symptoms. And we all know that
Show less
Read more
Impact Snapshot
Event Time:
NERV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NERV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NERV alerts
High impacting Minerva Neurosciences, Inc news events
Weekly update
A roundup of the hottest topics
NERV
News
- Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026GlobeNewswire
- Minerva Neurosciences (NASDAQ:NERV) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NERV&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of DirectorsGlobeNewswire
- Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
NERV
Earnings
- 5/13/25 - Beat
NERV
Sec Filings
- 2/3/26 - Form 8-K
- 1/7/26 - Form EFFECT
- 1/6/26 - Form 424B3
- NERV's page on the SEC website